QurAlis is a technology company.
QurAlis has raised $136.0M across 3 funding rounds.
Key people at QurAlis.
QurAlis has raised $136.0M in total across 3 funding rounds.
QurAlis Corporation is a clinical-stage biotechnology company developing precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.[1][5] It builds therapies using proprietary stem cell-derived neuronal models, the FlexASO™ splice modulator platform, and targets like Kv7.2, STATHMIN-2 (STMN2), and UNC13A to address genetic drivers in sporadic ALS and related conditions, serving patients with these devastating diseases where few effective treatments exist.[1][3][7] The company advances a robust pipeline, including three programs—two in clinical stages—with lead candidates like QRL-201 (STMN2) and QRL-101 (Kv7), demonstrating strong growth through milestones like first-in-human dosing, regulatory approvals, and Series B financing.[3][7]
QurAlis was founded on December 12, 2016, in Cambridge, MA, by Drs. Kasper Roet, Kevin Eggan, and Clifford Woolf, alongside Q-State Biosciences—all internationally recognized neurodegenerative biologists from Harvard Medical School and Harvard University.[1][7] Eggan pioneered patient-derived stem cell technology for neuronal models, enabling identification of key ALS genetic targets like Kv7.2 and STATHMIN-2.[1] Early traction included launching three precision medicine programs for ALS subgroups in 2017, winning the Amgen Golden Ticket, selecting QRL-201 as lead candidate in 2021, and achieving pivotal 2023 milestones: first-in-human dosing of QRL-101, Series B raise, new UNC13A program reveal, and clinical trial authorizations (CTAs) from Health Canada, EU, and UK for QRL-201, with first patient dosing.[7]
QurAlis rides the wave of precision medicine in neurodegeneration, cracking sporadic ALS via TDP-43-linked drivers like STMN2 and UNC13A mis-splicing, enabled by stem cell tech and ASO advances.[1][5] Timing aligns with rising genetic insights and regulatory support for orphan diseases, amplified by market forces like urgent ALS unmet needs (few disease-modifying therapies) and biotech investment in RNA-targeted drugs.[2][7] It influences the ecosystem by pioneering sub-type specific treatments, collaborating with thought leaders and advocates, and expanding platforms to neurological disorders, potentially reshaping outcomes for genetically defined patient groups.[3][4]
QurAlis is poised to deliver first-in-class precision therapies, with clinical data from QRL-101 and QRL-201 expected to validate its platforms and drive partnerships or further funding.[7] Trends like ASO maturation, biomarker-driven trials, and global manufacturing will accelerate its pipeline expansion into FTD, epilepsy, and beyond, potentially altering neurodegenerative treatment paradigms.[3][6] As neuro pioneers, QurAlis' relentless focus on patient-derived insights and genetic precision positions it to lead breakthroughs, bringing hope to ALS and FTD communities through trajectory-altering medicines.[1][5]
QurAlis has raised $136.0M in total across 3 funding rounds.
QurAlis's investors include 15th Rock Ventures, Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, Brandon Capital Partners, EQT Life Sciences, Scott Biller, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Northpond Ventures, Polaris Partners.
Key people at QurAlis.
QurAlis has raised $136.0M across 3 funding rounds. Most recently, it raised $88.0M Series B in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $88.0M Series B | 15th Rock Ventures, Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, Brandon Capital Partners, EQT Life Sciences, Scott Biller, INKEF Capital, Mission BioCapital, MP Healthcare Venture Management, Northpond Ventures, Polaris Partners, Sanofi Ventures | |
| May 1, 2020 | $42.0M Series A | Amadeus Capital Partners, AMR Action Fund, Oscar Slotboom, EQT Life Sciences, INKEF Capital, Mission BioCapital, Polaris Partners | |
| Nov 1, 2018 | $6.0M Seed | AMR Action Fund, Brandon Capital Partners, Mission BioCapital, MP Healthcare Venture Management |
